EP
PTGX icon

Eversept Partners’s Protagonist Therapeutics PTGX Stock Holding History

Eversept Partners’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.17M Buy
+58,504
New +$6.11M 0.37% 59
2026
Q1 		– Sell
-52,961
Closed -$4.63M – 143
2025
Q4 		$4.63M Buy
+52,961
New +$4.33M 0.23% 72
2025
Q3 		– Sell
-277,316
Closed -$15.3M – 98
2025
Q2 		$15.3M Sell
277,316
-269,800
-49% -$12.9M 1.41% 26
2025
Q1 		$26.5M Sell
547,116
-131,671
-19% -$5.52M 2.69% 11
2024
Q4 		$26.2M Buy
678,787
+233,583
+52% +$10.2M 2.33% 11
2024
Q3 		$20M Sell
445,204
-60,632
-12% -$2.45M 1.37% 19
2024
Q2 		$17.5M Buy
505,836
+94,358
+23% +$2.76M 1.2% 20
2024
Q1 		$11.9M Sell
411,478
-126,596
-24% -$3.44M 0.79% 24
2023
Q4 		$12.3M Buy
538,074
+251,326
+88% +$4.4M 1.08% 22
2023
Q3 		$4.78M Buy
286,748
+172,089
+150% +$3.34M 0.4% 42
2023
Q2 		$3.17M Buy
+114,659
New +$2.87M 0.26% 51

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Eversept Partners's PTGX Position: Q2 2026 in Review

Eversept Partners opened a new position in Protagonist Therapeutics (PTGX) in Q2 2026: 58,504 shares worth $7.17M. The stake represents 0.37% of the portfolio and ranks #59 among its holdings. This is a return to the name: Eversept Partners previously reported a position in PTGX as recently as Q4 2025.

Eversept Partners first reported a position in PTGX in Q2 2023 and has held it in 11 quarters since. The position peaked at $26.5M in Q1 2025. 344 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Eversept Partners held 58,504 shares of Protagonist Therapeutics worth $7.17M as of Q2 2026.
  • Protagonist Therapeutics was a new Eversept Partners position in Q2 2026.
  • Protagonist Therapeutics made up 0.37% of Eversept Partners's portfolio in Q2 2026, its #59 holding.
  • Eversept Partners first reported a position in Protagonist Therapeutics in Q2 2023 and has held it in 11 quarters since.
  • Eversept Partners's Protagonist Therapeutics position peaked at $26.5M in Q1 2025.
  • 344 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Eversept Partners's 13F filing for Q2 2026, filed 14 Aug 2026.